Photochemical internalization-mediated delivery of chemotherapeutic agents in human breast tumor cell lines

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 31, Issue 1, 2012, Pages 49-59

  Mathews, Marlon S ^a,b   Vo, Van ^c   Shih, En Chung ^b   Zamora, Genesis ^b   Sun, Chung Ho ^b   Madsen, Steen J ^c   Hirschberg, Henry ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEVADA   (United States)

Author keywords

Breast cancer chemotherapy; Chemotherapeutic resistance; Photochemical internalization; Photodynamic therapy

Indexed keywords

ANNEXIN; BLEOMYCIN; CISPLATIN; CISPLATIN DERIVATIVE; DICHLORO(4,4' DIPROPYL 2,2' BIPYRIDINE)PLATINUM; DOXORUBICIN; PHTHALOCYANINE ALUMINUM; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL DEATH; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DIODE LASER; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; ILLUMINATION; MONOTHERAPY; PHOTOCHEMICAL INTERNALIZATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

EID: 84861886067     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v31.i1.60     Document Type: Article

References (58)

1. Bellon JR, Harris EE, Arthur DW, Bailey L, Carey L, Goyal S, Halyard MY, Horst KC, Moran MS, Macdonald SM, Haffty BG. ACR Appropriateness Criteria ® conservative surgery and radiation-stage I and II breast carcinoma: expert panel on radiation oncology: breast. Breast J. 2011;17:448-455.
2. Subhas G, Shah AJ, Gupta A, Cook J, Dubay L, Silapaswan S, Kolachalam R, Kestenberg W, Ferguson L, Jacobs MJ, Goriel Y, Mittal VK. Review of third and fourth re-excision for narrow or positive margins of invasive and intraductal carcinoma. Int Surg. 2011;96(1):18-20.
3. Sanchez C, Brem RF, McSwain AP, Rapelyea JA, Torrente J, Teal CB. Factors associated with reexcision in patients with early-stage breast cancer treated with breast conservation therapy. Am Surg. 2010;76(3):331-334.
4. Horst KC, Smitt MC, Goffinet DR, Carlson RW. Predictors of local recurrence after breast-conservation therapy. Clin Breast Cancer. 2005;5(6):425-438.
5. Jalali R, Singh S, Budrukkar A. Techniques of tumour bed boost irradiation in breast conserving therapy: current evidence and suggested guidelines. Acta Oncol. 2007;46(7):879-892.
6. Graham P, Fourquet A. Placing the boost in breastconservation radiotherapy: areview of the role, indications and techniques for breast-boost radiotherapy. Clin Oncol (R Coll Radiol). 2006;18(3):210-219.
7. Fitzal F, Mittlboeck M, Steger G, Bartsch R, Rudas M, Dubsky P, Riedl O, Jakesz R, Gnant M. Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients. Ann Surg Oncol. 2011;19:519-526.
8. Bear HD. Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy. Surg Oncol Clin N Am. 2010;19(3):607-626.Review.
9. Wang J, Shi M, Ling R, Xia Y, Luo S, Fu X, Xiao F, Li J, Long X, Wang J, Hou Z, Chen Y, Zhou B, Xu M. Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiother Oncol. 2011;100:200-204.
10. Li FY, He ZY, Xue M, Chen LX, Wu SG, Guan XX. Feasibility and acute toxicity of 3-dimensional conformal external-beam accelerated partial-breast irradiation for early-stage breast cancer after breastconserving surgery in Chinese female patients. Chin Med J (Engl). 2011;124(9):1305-1309.
11. Sharp L, Johansson H, Landin Y, Moegelin IM, Bergenmar M. Frequency and severity of skin reactions in patients with breast cancer undergoing adjuvant radiotherapy, the usefulness of two assessment instruments - a pilot study. Eur J Cancer. 2011;47:2665-2672.
12. Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip AY, Glück S. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer. 2011;47:2537-2545.
13. Yaal-Hahoshen N, Maimon Y, Siegelmann-Danieli N, Lev-Ari S, Ron IG, Sperber F, Samuels N, Shoham J, Merimsky O. A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer. Oncologist. 2011;16:1197-1202.
14. Madarnas Y, Dent SF, Husain SF, Robinson A, Alkhayyat S, Hopman WM, Verreault JL, Vandenberg T. Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres. Curr Oncol. 2011;18:119-125.
15. Staudacher L, Cottu PH, Diéras V, Vincent-Salomon A, Guilhaume MN, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga JY. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol. 2011;22(4):848-856.
16. Ostrow S, Egorin M, Aisner J, Bachur N, Wiernik PH. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: Ppharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials. 1980;3(1):23-27.
17. Forastiere AA, Hakes TB, Wittes JT, Wittes RE. Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol. 1982;5(3):243-247.
18. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95(4):1650-1659.
19. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62(17):4899-4902.
20. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H. Overexpression of cMOAT (MRP2/ ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol. 2003;121(1):172-176.
21. Feng Z, Lai Y, Ye H, Huang J, Xi XG, Wu Z. Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: a comparative study with clinically used platinum derivatives. Cancer Sci. 2010;101(11):2476-2482.
22. Vrzal R, Starha P, Dvorák Z, Trávnícek Z. Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands. J Inorg Biochem. 2010;104(10):1130-1132.
23. Berg K, Selbo PK, Prasmickaite L, Tjelle TE, Sandvig K, Moan J, Gaudernack G, Fodstad O, Kjølsrud S, Anholt H, Rodal GH, Rodal SK, Høgset A. Photochemical internalization: a novel technology for delivery of macromolecules into cytosol. Cancer Res. 1999;59(6):1180-1183.
24. Martinez M, Pramanik A, Moto-Ndje S, Moore CW. Overexpression of genes involved in vesicular trafficking to the vacuole defends against lethal effects of oxidative damage. Cell Mol Biol (Noisy-legrand). 2003;49(7):1025-1035.
25. Selbo PK, Sivam G, Fodstad O, Sandvig K, Berg K. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy. Int J Cancer. 2001;92(5):761-766.
26. Berg K, Dietze A, Kaalhus O, Høgset A. Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin. Clin Cancer Res. 2005;11(23):8476-8485.
27. Norum OJ, Giercksky KE, Berg K. Photochemical internalization as an adjunct to marginal surgery in a human sarcoma model. Photochem Photobiol Sci. 2009;8(6):758-762.
28. Drewinko B, Loo TL, Brown B, Gottlieb JA, Freireich EJ. Combination chemotherapy in vitro with adriamycin. Cancer Biochem Biophys. 1976;1(4):187-195.
29. Breast cancer statistics [page on the Internet]. Atlanta, GA: Centers for Disease Control and Prevention. 23 Nov 2010 [cited Nov 2011]. Available from: http://www.cdc.gov/cancer/breast/statistics.
30. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22.
31. Soudy R, Gill A, Sprules T, Lavasanifar A, Kaur K. Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells. J Med Chem. 2011;54(21):7523-7534.
32. Musa MA, Khan MO, Cooperwood JS. Synthesis and antiproliferative activity of coumarin-estrogen conjugates against breast cancer cell lines. Lett Drug Des Discov. 2009;6(2):133-138.
33. Fox BP, Kandpal RP. EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells. Oncogene. 2009;28(14):1706-1713.
34. Zen K, Liu DQ, Guo YL, Wang C, Shan J, Fang M, Zhang CY, Liu Y. CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration. PLoS One. 2008;3(3):e1826.
35. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307-320.
36. Danford AJ, Wang D, Wang Q, Tullius TD, Lippard SJ. Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proc Natl Acad Sci U S A. 2005;102(35):12311-12316.
37. Vo V, Kabuloglu-Karayusuf ZG, Carper SW, Bennett BL, Evilia C. Novel 4,4'-diether-2,2'-bipyridine cisplatin analogues are more effective than cisplatin at inducing apoptosis in cancer cell lines. Bioorg Med Chem. 2010;18(3):1163-1170.
38. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta. 1986;857(1):123-126.
39. Coley HM, Amos WB, Twentyman PR, Workman P. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthra-cyclines in parent and multidrug resistant cell lines. Br J Cancer. 1993;67:1316-1323.
40. Gervasoni JE, Fields SZ, Krishna S, Baker MA, Rosado M, Thuraisamy K, Hindenburg AA, Taub RN. Subcellular distribution of daunorubicin in Ppharmacokinetics glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res. 1991;51:4955-4963.
41. Weaver JL, Pine PS, Aszalos A, Schoenlein PV, Currier SJ, Padmanabhan R, Gottesman MM. Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug-resistant cells. Exp Cell Res. 1991;196:323-332.
42. Selbo PK, Weyergang A, Bonsted A, Bown SG, Berg K. Photochemical internalization of therapeutic macromolecular agents: a novel strategy to kill multidrug-resistant cancer cells. J Pharmacol Exp Ther. 2006;319(2):604-612.
43. Lou PJ, Lai PS, Shieh MJ, Macrobert AJ, Berg K, Bown SG. Reversal of doxorubicin resistance in breast cancer cells by photochemical internalization. Int J Cancer. 2006;119(11):2692-2698.
44. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther. 2000;85:217-229.
45. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385-427.
46. Bellamy WT. P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-183.
47. Adigbli DK, Wilson DGG, Farooqui N, Sousi E, Risley P, Taylor I, MacRobert AJ, Loizidou M. Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells. Br J Cancer. 2007;97:502-512.
48. Van V. Cytotoxicity of novel cisplatin analogs in lung, prostate and breast cancer cells [Masters thesis]. Las Vegas (NV): University of Nevada; 2007.
49. Norum OJ, Gaustad JV, Angell-Petersen E, Rofstad EK, Peng Q, Giercksky KE, Berg K. Photochemical internalization of bleomycin is superior to photodynamic therapy due to the therapeutic effect in the tumor periphery. Photochem Photobiol. 2009;85(3):740-749.
50. Zaniboni A, Prabhu S, Audisio RA. Chemotherapy and anesthetic drugs: too little is known. Lancet. 2005;6:176-181.
51. Pron G, Mahrour N, Orlowski S. Internalization of the bleomycin molecules responsible for bleomycin toxicity: a receptor-mediated endocytosis mechanism. Biochem Pharmacol. 1999;57:45-56.
52. Poddevin B, Orlowski S, Belehradek J, Mir LM. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol. 1991;42:S67-75.
53. Hirschberg H, Madsen S, Lote K, Chen T, Tromberg B. An indweling balloon catheter for combined postoperative intracavity photodynamic and brachytherapy. J Neurooncol 1999;44:15-21.
54. Johannesen TB, Watne K, Lote K, Norum J, Henning R, Tvera K, Hirschberg H. Intracavity fractionated balloon brachytherapy in glioblastoma. Acta Neurchiurica. 1999;141(2):127-133.
55. Madsen SJ, Svaasand LO, Tromberg BJ, H Hirschberg H. Characterization of the light distribution from an intracranial balloon applicator for photodynamic therapy. In: Duncan DD, Jacques SL, Johnson PC, editors. Laser-tissue interaction XII: photochemical, photothermal and photomechanical (proceedings volume). Vol. 4257. Bellingham (WA): SPIE; 2001. p.
56. Madsen SJ, Sun CH, Tromberg BJ, Hirschberg H. Development of a novel indwelling balloon applicator for optimizing light delivery in photodynamic therapy. Lasers Surg Med. 2001;29(5):406-412.
57. Wilder RB, Curcio LD, Khanijou RK, Eisner ME, Kakkis JL, Chittenden L, Agustin J, Lizarde J, Mesa AV, Macedo JC, Ravera J, Tokita KM. Preliminary results in 173 breast cancer patients treated with post-lumpectomy mammosite singlelumen brachytherapy or multi-catheter brachytherapy. Breast J. 2010;16(6):581-586.
58. Harper JL, Watkins JM, Zauls AJ, Wahlquist AE, Garrett-Mayer E, Baker MK, Cole DJ, Dragun AE, Jenrette JM 3rd. Six-year experience: long-term disease control outcomes for partial breast irradiation using MammoSite balloon brachytherapy. Am J Surg. 2010;199(2):204-209.